Skip to main content
. 2021 Feb 26;11(3):296. doi: 10.3390/brainsci11030296

Table 3.

SMA patients with or without CSF–blood barrier dysfunction according to age-adjusted reference levels for QAlbumin throughout therapy (d0 to m22). CSF: cerebrospinal fluid; d: day; m: month; SMA: spinal muscular atrophy.

Time Point n CSF–Blood Barrier Dysfunction
Yes No
d0 24 6 (25%) 18
d14 19 3 (15.8%) 16
d28 14 1 (7.1%) 13
d63 22 7 (31.8%) 15
m6 18 7 (38.9%) 11
m10 17 5 (29.4%) 12
m14 13 3 (23.1%) 10
m18 6 2 (33.3%) 4
m22 2 0 2